Table 1 Comparison between Progressors and Non-progressors .

Age at first diagnosis of advanced glaucoma (years)

54.25 ± 14.09

53.90 ± 13.73

0.885^a

Gender (n, %)

 Male

31 (52.5)

37 (54.4)

0.860^b

 Female

28 (47.5)

31 (45.6)

 Diabetes mellitus (n, %)

11 (18.6)

12 (17.6)

0.884^b

 Hypertension (n, %)

27 (45.8)

16 (23.5)

0.008^b

 History of glaucoma surgery (n, %)

9 (13.2)

2 (3.4)

0.061^b

 Follow-up duration (years)

11.58 ± 3.19

11.28 ± 3.37

0.272^a

 Baseline BCVA (logMAR)

0.04 ± 0.15

0.09 ± 0.20

0.114^a

 Final BCVA (logMAR)

0.29 ± 0.54

0.24 ± 0.38

0.504^a

 Spherical equivalent

 − 2.89 ± 4.56

 − 2.50 ± 3.84

0.611^a

 Central corneal thickness (μm)

531.49 ± 41.36

524.92 ± 26.44

0.335^a

 Axial length (mm)

25.19 ± 2.34

24.55 ± 1.44

0.094^a

IOP (mmHg)

 Baseline IOP

16.56 ± 4.34

17.68 ± 5.81

0.218^a

 Mean IOP during follow-up

13.05 ± 1.75

12.87 ± 2.17

0.626^a

 Percentage reduction of IOP (%)

19.36 ± 13.98

21.67 ± 16.88

0.123^a

 IOP fluctuation during follow-up

2.02 ± 0.84

2.18 ± 0.88

0.296^a

OCT RNFL thickness (μm)

 Baseline average RNFL thickness

65.92 ± 8.65

61.34 ± 10.15

0.007^a

 Final average RNFL thickness

59.22 ± 7.85

56.89 ± 8.40

0.113^a

OCT GCIPL thickness (μm)

 Baseline average macular GCIPL thickness

63.72 ± 8.04

60.83 ± 7.63

0.044^a

 Final average macular GCIPL thickness

58.02 ± 7.88

57.59 ± 8.35

0.771^a

SAP 24-2 VFI (%)

 Baseline VFI

63.51 ± 14.42

49.88 ± 17.49

 < 0.001^a

 Final VFI

44.69 ± 17.03

44.29 ± 17.44

0.896^a

SAP 24-2 MD (dB)

 Baseline MD

− 12.77 ± 4.17

− 16.80 ± 5.56

 < 0.001^a

 Final MD

− 19.04 ± 4.73

− 19.09 ± 5.27

0.956^a

Disc hemorrhage (% positive)

7 (11.9)

1 (1.5)

0.016^b